These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 35485527)
21. Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging. Hess CP; Christine CW; Apple AC; Dillon WP; Aminoff MJ AJNR Am J Neuroradiol; 2014 May; 35(5):897-903. PubMed ID: 24356677 [TBL] [Abstract][Full Text] [Related]
22. α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Fernandes Gomes B; Farris CM; Ma Y; Concha-Marambio L; Lebovitz R; Nellgård B; Dalla K; Constantinescu J; Constantinescu R; Gobom J; Andreasson U; Zetterberg H; Blennow K Parkinsonism Relat Disord; 2023 Dec; 117():105807. PubMed ID: 37591709 [TBL] [Abstract][Full Text] [Related]
23. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Buée L; Delacourte A Brain Pathol; 1999 Oct; 9(4):681-93. PubMed ID: 10517507 [TBL] [Abstract][Full Text] [Related]
24. Genetic pleiotropy and the shared pathological features of corticobasal degeneration and progressive supranuclear palsy: a case report and a review of the literature. Rini J; Asken B; Geier E; Rankin K; Kramer J; Boxer A; Miller B; Yokoyama J; Spina S Neurocase; 2021 Apr; 27(2):120-128. PubMed ID: 33754963 [TBL] [Abstract][Full Text] [Related]
25. A disease-specific metabolic brain network associated with corticobasal degeneration. Niethammer M; Tang CC; Feigin A; Allen PJ; Heinen L; Hellwig S; Amtage F; Hanspal E; Vonsattel JP; Poston KL; Meyer PT; Leenders KL; Eidelberg D Brain; 2014 Nov; 137(Pt 11):3036-46. PubMed ID: 25208922 [TBL] [Abstract][Full Text] [Related]
26. Dual pathology of corticobasal degeneration and Parkinson's disease in a patient with clinical features of progressive supranuclear palsy. Mooney T; Tampiyappa A; Robertson T; Grimley R; Burke C; Ng K; Patrikios P Neurol India; 2011; 59(6):887-90. PubMed ID: 22234205 [TBL] [Abstract][Full Text] [Related]
27. [Autonomic Dysfunction in Tauopathies]. Koga S; Aiba I Brain Nerve; 2022 Mar; 74(3):257-262. PubMed ID: 35260524 [TBL] [Abstract][Full Text] [Related]
28. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721 [TBL] [Abstract][Full Text] [Related]
29. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385 [TBL] [Abstract][Full Text] [Related]
30. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Stamelou M; Respondek G; Giagkou N; Whitwell JL; Kovacs GG; Höglinger GU Nat Rev Neurol; 2021 Oct; 17(10):601-620. PubMed ID: 34426686 [TBL] [Abstract][Full Text] [Related]
31. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765 [TBL] [Abstract][Full Text] [Related]
33. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Stamelou M; Quinn NP; Bhatia KP Mov Disord; 2013 Aug; 28(9):1184-99. PubMed ID: 23720239 [TBL] [Abstract][Full Text] [Related]
34. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis. Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266 [TBL] [Abstract][Full Text] [Related]
35. Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. Mimuro M; Yoshida M Neuropathology; 2020 Feb; 40(1):57-67. PubMed ID: 31515852 [TBL] [Abstract][Full Text] [Related]
36. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991 [TBL] [Abstract][Full Text] [Related]
37. The glial marker YKL-40 is decreased in synucleinopathies. Olsson B; Constantinescu R; Holmberg B; Andreasen N; Blennow K; Zetterberg H Mov Disord; 2013 Nov; 28(13):1882-5. PubMed ID: 23847144 [TBL] [Abstract][Full Text] [Related]
38. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Ling H; O'Sullivan SS; Holton JL; Revesz T; Massey LA; Williams DR; Paviour DC; Lees AJ Brain; 2010 Jul; 133(Pt 7):2045-57. PubMed ID: 20584946 [TBL] [Abstract][Full Text] [Related]
39. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796 [TBL] [Abstract][Full Text] [Related]